The Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 pipeline drugs market research report outlays comprehensive information on the Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Solid Tumor. It also reviews key players involved in Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 4, and 1 respectively.
Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1 overview
Leukocyte immunoglobulin like receptor subfamily B member 1 (LILRB1) is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. LILRB1 is a receptor for class I MHC antigens which recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis.
For a complete picture of Leukocyte Immunoglobulin Like Receptor Subfamily B Member 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
